ReviewThe Lancet. Infectious diseases2023
Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection.
Review in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Treatment of Severe Ocular Mpox with Cidofovir and Tecovirimat.Emerging infectious diseases · 2026Article
- Primary human intestinal organoids model enteric infection of monkeypox virus and enable scalable drug discovery.Science advances · 2026Article
- The Emerging Threat of Monkeypox: An Updated Overview.Viruses · 2026Review
- Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice.Nature communications · 2025Article
- Mpox: Global epidemic situation and countermeasures.Virulence · 2025Review
- Mpox in People Living with HIV: Clinical Challenges, Preventive Strategies and Public Health Implications.Viruses · 2025Review
- From neglected to notoriety: a review of Mpox clinical features, virology, epidemiology, treatment and prevention strategies.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Neurological complications of Orthopoxvirus infections: neurotropism and neurovirulence.Brain : a journal of neurology · 2025Review
- Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Advanced healthcare materials · 2025Review
- Repurposing doxycycline for the inhibition of monkeypox virus DNA polymerase: a comprehensive computational study.In silico pharmacology · 2025Article
- A retrospective genomic characterisation of the 2022 mpox outbreak in Belgium, and in vitro assessment of three antiviral compounds.EBioMedicine · 2024Article
- What every intensivist needs to know about mpox.Critical care (London, England) · 2024Article
- Mpox Recurrence and Tecovirimat Resistance in a Patient With Advanced Human Immunodeficiency Virus Disease.Open forum infectious diseases · 2024Article
- Mpox: what sexual health physicians need to know?International journal of impotence research · 2024Review
- Orally available nucleoside analog UMM-766 provides protection in a murine model of orthopox disease.Microbiology spectrum · 2024Article
- Challenges in Managing Treatment-Resistant Mpox Complicated by Severe Superinfection.Open forum infectious diseases · 2024Article
- Intriguing insight into unanswered questions about Mpox: exploring health policy implications and considerations.Health research policy and systems · 2024Article
- Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced Human Immunodeficiency Virus Infection: Case Series of 4 Patients.Open forum infectious diseases · 2024Article
- Update on Mpox: What the Primary Care Clinician Should Know.The Medical clinics of North America · 2024Review
- Clinical characteristics, viral dynamics, and antibody response of monkeypox virus infections among men with and without HIV infection in Guangzhou, China.Frontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 48-year-old man with poorly controlled HIV presented with severe human monkeypox virus (hMPXV) infection, having completed 2 weeks of tecovirimat at another hospital. He had painful, ulcerating skin lesions on most of his body and oropharyngeal cavity, with subsequent Ludwig's angina requiring repeated surgical interventions. Despite commencing a second, prolonged course of tecovirimat, he did not objectively improve, and new lesions were still noted at day 24. Discussion at the UK National Health Service England High Consequence Infectious Diseases Network recommended the use of 3% topical and then intravenous cidofovir, which was given at 5 mg/kg; the patient made a noticeable improvement after the first intravenous dose. He received further intravenous doses at 7 days and 21 days after the dose and was discharged at day 52. Cidofovir is not licensed for use in treatment of hMPXV infection. Data for cidofovir use in hMPXV are restricted to studies in animals. Four other documented cases of cidofovir use against hMPXV have been reported in the USA in 2022, but we present its first use in the UK. The scarcity of studies into the use of cidofovir in this condition clearly shows the need for robust studies to assess efficacy, optimum dosage, timing, and route of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.